Q3 2022 Financial Results & Business Update

Nov. 14, 2022

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as "believes," "expects," "anticipates," "could," "would," "seeks," "aims," "plans," "potential," "will" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen's business, Acumen's ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the sufficiency of its cash resources, and the therapeutic potential of Acumen's product candidate, ACU193, including its potential for improved safety and efficacy as compared to other monoclonal antibodies in development, as well as the expectations concerning the INTERCEPT-AD trial and Acumen's planned Phase 2/3 clinical trial, including the expected timing of initiation, enrollment and reporting data, and risks and uncertainties relating to the progression and duration of the COVID-19 pandemic and responsive measures thereto and related effects on Acumen. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of the COVID-19 pandemic. These and other risks concerning Acumen's programs are described in additional detail in Acumen's filings with the Securities and Exchange Commission ("SEC"), including in Acumen's Form 10-K for the year ended December 31, 2021, Acumen's Form 10-Q for the quarter ended September 30, 2022, and future filings and reports by Acumen. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise. In this presentation, references to cash also include cash equivalents.

ACUMEN

Agenda

- **Q3 2022 Business Update**

  Dan O'Connell, Chief Executive Officer

- **ACU193 Momentum and Alzheimer's Landscape Update**

  Dr. Eric Siemers, Chief Medical Officer

- **Q3 2022 Financial Results**

  Matt Zuga, Chief Business Officer & Chief Financial Officer

INTERCEPT-AD Trial Update – 3Q 2022

- **INTERCEPT-AD: Phase 1 clinical trial of ACU193 in patients with early Alzheimer's disease (AD) (RCT)**
  - → Trial enrollment ongoing at 17 active sites
    - Enrollment completion expected in 1Q 2023
  - → Topline results (proof-of-mechanism) following full database lock expected in 2H 2023
    - Safety / ARIA-E
    - PK
    - Target engagement

- **Phase 2/3 'Ready' Activities**
  - → Chronic GLP toxicity study in-life phase completed; final study report expected in 1Q 2023
  - → Well-positioned to efficiently scale manufacturing to have sufficient drug supply to meet the requirements of our current development plan
  - → Confirmation of ACU193's IgG2 antibody subclass; maintain expectation that reduced effector function should favorably influence ACU193 safety outcomes

ACU193 Fast Track Designation and Clinical Development Plan

- **In October 2022, ACU193 granted Fast Track designation for the treatment of early Alzheimer's disease by the U.S. Food and Drug Administration (FDA)**

  → Reflects potential clinical utility of ACU193 to treat early AD

- **Also in October 2022, development rationale and clinical development plan for ACU193 was published in the *Journal for Prevention of Alzheimer's Disease***

  → Outlines the design of our ongoing Phase 1 INTERCEPT-AD trial and planned criteria for advancing to a Phase 2/3 clinical trial based on recent advancements in clinical research on Alzheimer's disease

  - Phase 2/3 trial would initiate with patient sample size typical of a Phase 2 trial
  - Interim analysis to determine whether to increase the sample size to meet statistical power of a typical Phase 3 trial
  - Interim analysis may be based on several cognitive measures and various biomarkers, including phosphorylated tau in the blood and cerebrospinal fluid (CSF)
  - Pending discussions with regulators, if the interim analysis is positive, and the trial is expanded, the Phase 2/3 trial could potentially serve as a registrational trial

Acumen is Well Capitalized, With Expected Cash Runway Through 2025

MILESTONES	STATUS/ EXPECTED TIMING
Initiated Ph1 clinical trial INTERCEPT-AD	✓
INTERCEPT-AD enrollment complete	1Q 2023
Proof-of-mechanism topline results	2H 2023

~$200M

Cash, cash equivalents and marketable securities as of September 30, 2022

We believe that Acumen has the organizational expertise and cash and marketable securities on hand to advance ACU193 through 2025.

ACUMEN